PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
Executive Summary
FDA will have the authority to require manufacturers to inform prescribers if they fail to complete Phase IV commitments under the Prescription Drug User Fee Act reauthorization
You may also be interested in...
Phase IV Studies Encounter Delays, Yield Mixed Data – Tufts Report
A survey of 61 post-marketing drug studies conducted by the Tufts Center for the Study of Drug Development concluded that almost half of those trials did not meet their projected completion date. The center released results of the report, which appears in the May/June Tufts CSDD Impact Report, May 15
Phase IV Studies Encounter Delays, Yield Mixed Data – Tufts Report
A survey of 61 post-marketing drug studies conducted by the Tufts Center for the Study of Drug Development concluded that almost half of those trials did not meet their projected completion date. The center released results of the report, which appears in the May/June Tufts CSDD Impact Report, May 15
BioShield Bill Creates “Emergency Use Authority” Tied To Monetary Penalties
FDA could license bioterrorism countermeasures for "emergency use" with the legal backing of monetary penalties to ensure companies comply with the agency's terms under the Senate's "BioShield" bill